Nuveen Asset Management LLC Decreases Stake in Encompass Health Co. (NYSE:EHC)

Nuveen Asset Management LLC decreased its position in Encompass Health Co. (NYSE:EHC - Free Report) by 4.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 529,201 shares of the company's stock after selling 23,866 shares during the period. Nuveen Asset Management LLC owned 0.53% of Encompass Health worth $48,872,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB increased its stake in Encompass Health by 87.8% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock valued at $27,000 after buying an additional 137 shares during the last quarter. Colonial Trust Co SC purchased a new stake in Encompass Health in the 4th quarter valued at about $29,000. Transce3nd LLC purchased a new stake in Encompass Health in the 4th quarter valued at about $40,000. CBIZ Investment Advisory Services LLC increased its stake in Encompass Health by 38.7% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock valued at $42,000 after buying an additional 127 shares during the last quarter. Finally, V Square Quantitative Management LLC grew its position in shares of Encompass Health by 43.8% during the 4th quarter. V Square Quantitative Management LLC now owns 581 shares of the company's stock valued at $54,000 after acquiring an additional 177 shares during the period. Hedge funds and other institutional investors own 97.25% of the company's stock.

Encompass Health Stock Up 0.2%

EHC opened at $121.15 on Tuesday. The company has a 50 day moving average of $105.97 and a 200 day moving average of $100.90. The company has a market cap of $12.21 billion, a PE ratio of 27.16, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91. Encompass Health Co. has a 12 month low of $82.74 and a 12 month high of $121.44. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $1.37 EPS for the quarter, topping the consensus estimate of $1.19 by $0.18. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. Encompass Health's revenue for the quarter was up 10.6% on a year-over-year basis. During the same period last year, the firm earned $1.12 EPS. On average, sell-side analysts expect that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be issued a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 0.56%. The ex-dividend date of this dividend is Tuesday, July 1st. Encompass Health's payout ratio is 14.05%.

Analysts Set New Price Targets

EHC has been the subject of a number of research reports. UBS Group increased their target price on shares of Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a research report on Monday, April 28th. Barclays increased their target price on shares of Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Truist Financial reissued a "buy" rating and set a $135.00 target price (up from $116.00) on shares of Encompass Health in a research report on Monday, April 28th. StockNews.com raised shares of Encompass Health from a "hold" rating to a "buy" rating in a research report on Sunday, May 11th. Finally, Royal Bank of Canada increased their target price on shares of Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a research report on Monday, April 28th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Encompass Health has an average rating of "Buy" and an average target price of $120.86.

Insider Buying and Selling at Encompass Health

In other news, insider Elissa Joy Charbonneau sold 4,279 shares of the firm's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total transaction of $498,974.19. Following the sale, the insider now owns 11,958 shares in the company, valued at approximately $1,394,422.38. This trade represents a 26.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP John Patrick Darby sold 10,000 shares of the firm's stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the sale, the executive vice president now owns 79,710 shares in the company, valued at approximately $9,149,910.90. This trade represents a 11.15% decrease in their position. The disclosure for this sale can be found here. Insiders own 2.00% of the company's stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.